主動(dòng)脈是人體內(nèi)*大的動(dòng)脈，把含氧的血液由心臟輸送到全身各個(gè)部位。位于血管壁的主動(dòng)脈內(nèi)皮細(xì)胞（AEC）經(jīng)常暴露于高血流動(dòng)力，誘導(dǎo)內(nèi)皮源性血管收縮和血管生長(zhǎng)調(diào)節(jié)的物質(zhì)生產(chǎn)變化。AEC也調(diào)節(jié)細(xì)胞粘附分子的表達(dá)來(lái)控制和微調(diào)的炎癥反應(yīng)和纖溶系統(tǒng)。這些生理特征使得AEC廣泛被應(yīng)用于研究?jī)?nèi)皮功能障礙機(jī)理、血管疾病和動(dòng)脈硬化的發(fā)病機(jī)理、以及新的疾病的治療技術(shù)的發(fā)展。
Sciencell研究實(shí)驗(yàn)室的ACE是從人主動(dòng)脈分離得到的，原代凍存，冰凍運(yùn)輸。每管細(xì)胞密度超過(guò)5×10^5/ml。細(xì)胞特性經(jīng)vWF/Factor VIII和CD31 (PECAM) 免疫熒光鑒定，能夠攝取DiI標(biāo)記乙酰化低密度脂蛋白(DiI-Ac-LDL)。本細(xì)胞經(jīng)檢測(cè)不含HIV-1、HBV、HCV、支原體、細(xì)菌、酵母菌和真菌。如采用ScienCell 實(shí)驗(yàn)室特制的培養(yǎng)基，可保證此細(xì)胞10倍增增殖。
推薦培養(yǎng)基：成纖維細(xì)胞培養(yǎng)基 (FM, Cat. #2301)
|
貨號(hào)
|
6100
|
|
產(chǎn)地
|
美國(guó)
|
|
縮寫
|
HAEC
|
|
規(guī)格
|
5 x 10^5 /1ml
|
|
用途
|
科研
|
|
儲(chǔ)存
|
液氮
|
|
運(yùn)輸
|
干冰
|
|
關(guān)鍵字
|
人主動(dòng)脈內(nèi)皮細(xì)胞 HAEC 人主動(dòng)脈內(nèi)皮細(xì)胞 HAEC 人主動(dòng)脈內(nèi)皮細(xì)胞 HAEC 人主動(dòng)脈內(nèi)皮細(xì)胞 HAEC 人主動(dòng)脈內(nèi)皮細(xì)胞 HAEC 人主動(dòng)脈內(nèi)皮細(xì)胞 HAEC 人主動(dòng)脈內(nèi)皮細(xì)胞 HAEC 人主動(dòng)脈內(nèi)皮細(xì)胞 HAEC
|
公司簡(jiǎn)介
|
合肥星肽生物科技有限公司作為專業(yè)的ScienCell中國(guó)代理商，專業(yè)經(jīng)營(yíng)實(shí)驗(yàn)室科研用原代細(xì)胞、原代細(xì)胞專用培養(yǎng)基、原代細(xì)胞無(wú)血清培養(yǎng)基、干細(xì)胞、干細(xì)胞培養(yǎng)基、干細(xì)胞無(wú)血清培養(yǎng)基的研究和開發(fā)。合肥星肽生物科技有限公司始終致力于為客戶提供可靠的研究材料以及方便快捷的服務(wù)，對(duì)購(gòu)買項(xiàng)目的前期資料提供,中期合同保證,后期貨物跟蹤到 *終售后的確保項(xiàng)目準(zhǔn)確到位，都有相關(guān)專業(yè)人士進(jìn)行維護(hù),確保您在合肥合肥星肽生物科技有限公司公司獲得*上等服務(wù)！
|
|
聯(lián)系方式
|
何經(jīng)理，合肥星肽生物科技有限公司，Tel：0551-63802898 400-8702-898，
E-mail：info@qingbio.com http://www.qkdn.cn QQ:514713116
|
1.) Zhao N, Watson N, Xu Z, Chen Y, Waterman J, Sankar J, Zhu D. (2014) "In Vitro Biocompatibility and Endothelialization of Novel Magnesium-Rare Earth Alloys for Improved Stent Applications." PloS one. 9: e98674.
2.) Wang W, Deng M, Liu X, Ai W, Tang Q, Hu J. (2011) "TLR4 Activation Induces Nontolerant Inflammatory Response in Endothelial Cells." Inflammation. 34: 509-18.
3.) Cai W, Torreggiani M, Zhu L, Chen X, He JC, Striker GE, Vlassara H. (2010) "AGER1 regulates endothelial cell NADPH oxidase-dependent oxidant stress via PKC-delta: implications for vascular disease." Am J Physiol Cell Physiol. 298: C624-34.
4.) Kong DK, Georgescu SP, Cano C, Aronovitz MJ, Iovanna JL, Patten RD, Kyriakis JM, Goruppi S. (2010) "Deficiency of the transcriptional regulator p8 results in increased autophagy and apoptosis, and causes impaired heart function." Mol Biol Cell. 21: 1335-49.
5.) Shahani T, Lavend'homme R, Luttun A, Saint-Remy JM, Peerlinck K, Jacquemin M. (2010) "Activation of human endothelial cells from specific vascular beds induces the release of a FVIII storage pool." Blood. 115: 4902-9.
6.) Zhang CL, Song F, Zhang J, Song QH. (2010) "Hypoxia-induced Bcl-2 expression in endothelial cells via p38 MAPK pathway." Biochem Biophys Res Commun. 394: 976-80.
7.) Linden E, Cai W, He JC, Xue C, Li Z, Winston J, Vlassara H, Uribarri J. (2008) "Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation." Clin J Am Soc Nephrol. 3: 691-8.
8.) Zhang X, Baughman CB, Kaplan DL. (2008) "In vitro evaluation of electrospun silk fibroin scaffolds for vascular cell growth." Biomaterials. 29: 2217-27.
9.) Gentry M, Taormina J, Pyles RB, Yeager L, Kirtley M, Popov VL, Klimpel G, Eaves-Pyles T. (2007) "Role of Primary Human Alveolar Epithelial Cells in Host Defense against Francisella tularensis Infection." Infect Immun. 75: 3969-78.
10.) Simard JM, Tsymbalyuk O, Ivanov A, Ivanova S, Bhatta S, Geng Z, Woo SK, Gerzanich V. (2007) "Endothelial sulfonylurea receptor 1-regulated NCCa-ATP channels mediate progressive hemorrhagic necrosis following spinal cord injury." J Clin Invest. 117: 2105-13.
There are no product questions yet.
